Several clinical trials have shown that, compared to other TPO-RAs, AVA is superior in treating certain thrombocytopenic diseases, such as primary ITP, AA, and chemotherapy-induced thrombocytopenia [18–22]. The gene discussed is TPO; the disease is Thrombocytopenia.